Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Russia

With over 150 international specialist lawyers across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the life sciences & healthcare sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

Feed

Show only
12 May 2021
Sig­ni­fic­ant changes made to cir­cu­la­tion pro­ced­ure for med­ic­al devices
On 11 May 2021, a law* came in­to force, which changes and sup­ple­ments the rules for the cir­cu­la­tion of med­ic­al devices. The main changes are as fol­lows: The pro­duc­tion of med­ic­al devices will...
05 May 2021
Com­pet­i­tion law en­force­ment in the phar­ma­ceut­ic­als sec­tor in Rus­sia
1. Is there any spe­cif­ic reg­u­lat­ory frame­work that deals with com­pet­i­tion reg­u­la­tion in the phar­ma­ceut­ic­al sec­tor in your coun­try? Form­ally, there is no spe­cif­ic reg­u­lat­ory frame­work for com­pet­i­tion...
Comparable
04 May 2021
With Il­lu­mina ac­tion, court to test EU Com­mis­sion's new mer­ger re­fer­ral...
On 29 April 2021, the US life sci­ences com­pany Il­lu­mina con­firmed that it filed an ac­tion be­fore the EU courts ask­ing for an an­nul­ment of the European Com­mis­sion’s de­cision of 19 April 2021 to ac­cept...
22 April 2021
Na­tion­al mar­ket­ing au­thor­isa­tions for med­ic­al devices will re­main val­id...
The Coun­cil of the Euras­i­an Eco­nom­ic Com­mis­sion has ap­proved* amend­ments to the Agree­ment on Com­mon Prin­ciples and Rules for the Cir­cu­la­tion of Med­ic­al Devices with­in the Euras­i­an Eco­nom­ic Uni­on dated...
20 April 2021
COV­ID-19 vac­cin­a­tion and test­ing in Rus­sia - em­ploy­ment law per­spect­ive
Vac­cin­a­tion 1. What op­tions does the em­ploy­er have to en­cour­age em­ploy­ees to be vac­cin­ated? Can the em­ploy­er provide a fin­an­cial in­cent­ive to em­ploy­ees?  The em­ploy­er may only en­cour­age em­ploy­ees...
Comparable
23 March 2021
The En­larged Board of the European Pat­ent Of­fice has giv­en a mo­ment­ous...
The En­larged Board of the European Pat­ent Of­fice heard or­al ar­gu­ments in Ju­ly 2020 con­cern­ing pat­entab­il­ity of a com­puter soft­ware in­ven­tion.  This rare event was video streamed to over 1600 pat­ent stake­hold­ers...
12 March 2021
CMS Rus­sia ex­perts re­cog­nised in the Pravo.ru-300 in­di­vidu­al rank­ing
The lead­ing na­tion­al leg­al dir­ect­ory Pravo.ru-300 has re­vealed the re­com­men­ded law­yers across 29 areas of law.This year sev­en CMS Rus­sia ex­perts have been ac­know­ledged by the rank­ing this year. Pravo.ru-300...
19 March 2021
Di­git­al Health: data pro­tec­tion chal­lenges in Rus­sia
We in­vite you for a CMS Rus­sia we­bin­ar on data pro­tec­tion chal­lenges re­lated to di­git­al health in Rus­sia. Join our ex­perts Ir­ina Shur­mina and Vladis­lav Eltovskiy to learn about:Leg­al grounds for pro­cessing...
12 February 2021
For­eign goods fur­ther squeezed out of Rus­si­an pub­lic pro­cure­ment
Quotas for goods of Rus­si­an ori­gin now ap­ply for state cus­tom­ers act­ing un­der Fed­er­al Laws No. 44-FZ* (state and mu­ni­cip­al en­tit­ies) and No. 223-FZ* (state-owned com­pan­ies). These changes were in­tro­duced...
1 February 2021
CMS suc­cess­fully de­fen­ded GE Health­care in a court of cas­sa­tion against...
CMS has suc­cess­fully de­fen­ded in­terests of GE Health­care in the court of ap­peal and fur­ther in the court of cas­sa­tion against the Rus­si­an health­care reg­u­lat­ory au­thor­ity (Roszdravn­ad­zor), in the case...
27 January 2021
Most awaited leg­al de­vel­op­ments of 2021
CMS Rus­sia ex­perts have pre­pared their an­nu­al se­lec­tion of the most awaited leg­al de­vel­op­ments in Rus­sia in 2021.You can read de­tailed art­icles and re­com­mend­a­tions by our ex­perts on the forth­com­ing changes...
11 January 2021
Rus­si­an gov­ern­ment is­sues first com­puls­ory phar­ma­ceut­ic­al li­cence
On 5 Janu­ary 2021, the Rus­si­an gov­ern­ment pub­lished an or­din­ance* on the is­su­ance of a com­puls­ory li­cence for in­ven­tions re­lated to the pro­duc­tion of re­m­desivir, a drug in­ten­ded for the treat­ment of COV­ID-19...